MT Group Information

MT Group is a leading biospecimen Contract Research Organization (CRO) that has been enhancing biomarker discovery and validation for pharmaceutical, biotechnology, and diagnostic companies since 2003. Founded by Dr. Thomas Moss (Chief Medical Officer) and Marc Siegel (President), we are headquartered in Los Angeles with a global site network spanning North America, South America, Europe, and Asia. What Sets Us Apart: * Prospective Expertise - Custom prospective collection expertise (although we do have a growing biobank). Expert in longitudinal collections and challenging to enroll populations. * Quality Guarantee - Robust collection and processing SOPs with detailed review of all biospecimens and metadata by our operational team. We stand behind our work with a quality replacement guarantee. * "MT Level" Metadata - Comprehensive clinical annotation including demographics, lifestyle, medical and therapeutic history, and outcomes. * Transparent Collaboration - Candid feedback about scientific and clinical feasibility of potential studies as well as open communication about ongoing study progress. * Global Network - 200+ US sites plus growing international reach. Our Expertise: * Biospecimen Types - Fresh, frozen & FFPE tissue, blood, serum, plasma, bone marrow, swabs, urine, saliva, and other samples. * Therapeutic Areas - Oncology, autoimmune disease (e.g. IBD, atopic dermatitis, psoriasis, arthritis), metabolic disease (e.g. obesity, diabetes, MASH/NASH, CKD), infectious disease, and many other areas. * Specialized Services - Longitudinal studies, clinical trial mimics, bridging studies. Proven Track Record: Over 20 years, we have completed hundreds of studies involving 10,000+ patients, supporting breakthrough medical advances from targeted therapy to immuno-oncology checkpoint inhibitors. https://mtgroupbio.com/